N🟁N

ARIAD to Present at the 27th Annual J.P. Morgan Healthcare Conference

  //health-fitness.news-articles.net/content/2009/ .. 7th-annual-j-p-morgan-healthcare-conference.html
  Published in Health and Fitness on Thursday, January 8th 2009 at 5:04 GMT, Last Modified on 2009-01-08 05:05:20 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 27th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will present on Thursday, January 15, 2009 at 10:30 a.m. (PT). Dr. Berger will provide an overview of the Company and its progress in key programs as well as top-line financial guidance for the company's fiscal year 2009.

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for four weeks.

About ARIAD

ARIAD's vision is to transform the lives of cancer patients with breakthrough medicines. The Company's mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD's lead product candidate, deforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD's second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit [ http://www.ariad.com ].